Home
Ultragenyx Pharmaceutical RARE paid Forbes-Tate $10K for lobbying in Q1 2026 · Health Issues
Trade details
- Type
- Lobbying report
- Amount
- $10,000
- Quarter
- Q1 2026
- Reported
- 26/04/20
$550K on lobbying this year
What else happened in Ultragenyx Pharmaceutical around then
Filed or reported within 30 days of the trade day · 03/01~04/30Ultragenyx Pharmaceutical's other lobbying reports
- Ultragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
RARE
$30K
$30K
Reported 07/20
for Q2
- Ultragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
RARE
$390K
$390K
Reported 07/20
for Q2
- Ultragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
RARE
$40K
$40K
Reported 07/20
for Q1
- Ultragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
RARE
$60K
$60K
Reported 07/20
for Q2
- Ultragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
LobbyingUltragenyx Pharmaceutical
RARE
$140K
$140K
Reported 07/20
for Q2